Dit artikel delen
Share this article
LEIDEN, The Netherlands, June 4, 2021 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that an agreement has been reached with the Spanish Ministry of Health to grant reimbursement for RUCONEST® (conestat alfa) in Spain.
RUCONEST® is the first and only plasma-free recombinant human C1 esterase inhibitor (rhC1INH) protein replacement therapy approved for the treatment of acute hereditary angioedema (HAE) attacks in adults and children aged 2 years and over.
1
HAE is a rare genetic condition characterized by recurrent, unpredictable episodic swellings of mucosal or cutaneous sites, causing pain, disfigurement, and disability, which last for hours and, occasionally, several days.
LEIDEN, The Netherlands, June 4, 2021 /PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that an agreement has been reached
WAALRE, The Netherlands, May 27, 2021 /PRNewswire/ IME Medical Electrospinning, global leader in fiber-based solutions for the medical industry, today announces the publication of the first
IME Medical Electrospinning helps shape the first standard on fiber-based medical scaffolds, published by ASTM International prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
IME Medical Electrospinning helps shape the first standard on fiber-based medical scaffolds, published by ASTM International prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.